Tarsus Pharmaceuticals, Inc.

TARS Nasdaq CIK: 0001819790

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 15440 LAGUNA CANYON ROAD, IRVINE, CA, 92618
Mailing Address 15440 LAGUNA CANYON ROAD, IRVINE, CA, 92618
Phone (949) 409-9820
Fiscal Year End 1231
EIN 814717861

Recent SEC Filings

Form Type Date Filed Document
SCHEDULE 13G/A Passive ownership amendment March 27, 2026 View on SEC
4 Insider stock transaction report March 24, 2026 View on SEC
4 Insider stock transaction report March 19, 2026 View on SEC
4 Insider stock transaction report March 19, 2026 View on SEC
4 Insider stock transaction report March 19, 2026 View on SEC
4 Insider stock transaction report March 19, 2026 View on SEC
4 Insider stock transaction report March 19, 2026 View on SEC
4 Insider stock transaction report March 19, 2026 View on SEC
4 Insider stock transaction report March 19, 2026 View on SEC
4 Insider stock transaction report March 18, 2026 View on SEC

Annual Reports

10-K February 23, 2026
  • Xdemvy's successful commercial launch drove product sales from $1 million in 2023 to $49 million in 2024, representing an impressive 4,800% year-over-year growth.
  • Tarsus secured substantial financing in 2024, including $17 million from public stock offerings and a new $150 million credit facility, strengthening its financial position.
View Analysis

Insider Trading

STRONG SELL 8 insiders 39 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.